Trial Profile
Phase II Trial of TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Antineoplastics; Ethiodized oil
- Indications Liver cancer
- Focus Therapeutic Use
- 30 May 2012 New trial record